Since elevated expression of HMG-CoAR and FAS in malignant cells has been documented in various cancers including breast, prostate, colon stomach, ovarian, endometrial, lung and hepatocellular carcinoma, compounds that can inhibit these enzymes in tumor cells, therefore, may be effective as adjuvant chemoterapeutic agents. Here, FAS is linked to hepatocellular carcinoma.